PANORAMIC

CPMS code:  51313

Lead Network: Thames Valley and South Midlands

Study Summary

Although vaccination has dramatically reduced the chances of getting COVID and becoming very unwell with it, many people still get so ill that they do need hospital treatment. Vaccines may not protect us fully against new variants of the virus that might develop. So far, a lot of the research has been to see if medicines used to treat other conditions might also work against COVID. Now, new ‘antiviral’ drugs have been developed which act directly against the virus that causes COVID, which could help people with COVID in the community avoid severe disease and hospitalisation. Our PANORAMIC study plans to enrol people either aged 50 or over or aged 18 or over with a medical condition which makes them at higher risk of severe COVID, who have recently developed COVID symptoms, and have had a positive PCR test. They will be randomly assigned by a computer program to receive either standard NHS care for COVID, or one of the new antiviral drugs in addition to the usual care provided by the NHS. People across the whole of the UK will be able to join the study. Our main question will be whether these new antiviral treatments safely help people with COVID-19 avoid the need for hospital admission. We will also test whether these drugs: - Shorten the length of time that people have symptoms of COVID. - Reduce the chance that people living with someone who has COVID also catches it. - Lessen the amount of the virus we shed when we are infected. - Are affected by new variants or changes in the virus once we start using them. - Offer value for money to the NHS. Our team has learned a lot from running the PRINCIPLE study; the world’s largest and most successful community-based trial looking at which existing drugs improve COVID symptoms and reduce the need for hospital admission. So far we have tested five different drugs in PRINCIPLE and nearly 6000 people with COVID have taken part. In this new PANORAMIC trial, we will build on our experience in PRINCIPLE by including more expertise from around the UK to make our study design more suited to testing new drugs, analysing viral samples, assessing value for money, and including patient representatives from diverse and disadvantaged backgrounds to deliver a world-leading study of novel treatments for COVID in the community. Findings will improve evidence supporting treatment for COVID world-wide. 

The search files hosted on this website are based on the inclusion/exclusion criteria as described in the study protocol and have been built and tested with input from our GP Champion teams. Every effort is made to keep the search files  hosted here maintained and up-to-date. 

However, it is the responsibility of the Principal Investigator to review the search and make any practice specific amendments as deemed necessary*. 

Please DO NOT mail out to patients until you have confirmation and sign off ('green light') from the study team.

*You should advise the study team of any amendments you make to the search.

Disclaimer:

Please note the resources provided are designed to assist with the identification of potentially suitable patients and to appropriately code these patients if required.

These resources have been developed based on the criteria provided by the relevant study team and whilst every effort has been made to make them universally implementable they rely on read codes and the data stored in the individual practice's clinical system. These resources are intended to assist with identification but should be used in conjunction with clinical oversight and a clear understanding of the study parameters.

While we endeavor to keep the information, tools and resources provided up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the tools provided for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of the tools provided.